Nuvilex, Inc. (OTCMKTS:NVLX) Hesitates Around The 25 Cent Mark

[[tagnumber 0]][[tagnumber 1]]Last month started quite well for the stock of Nuvilex, Inc. (OTCMKTS:NVLX) as it climbed the charts while in the same time having a moderate amount of investor interest. The final sessions, however, didn’t end well and NVLX was on a slide throughout the past week.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]A new press release managed to boost investor confidence in the beginning of this week. A little over an hour after market open on Monday [[tagnumber 6]]NVLX [[tagnumber 7]]announced that they will be commercializing the research made by Professor Ann Simpson and her colleagues at the University of Technology, Sydney for insulin producing cells which could eliminate the need for daily injections for patients with Type 1 or juvenile diabetes.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The optimistic news made an immediate impact on the ticker and [[tagnumber 6]]NVLX [[tagnumber 7]]began to go up the charts. Being a stock that rarely sees major percentile movements the 8% gain was more than decent. We also saw some increased investor attention as the 2.39 million shares that changed their owners during the session generated $576 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The company itself is in a decent financial position and should be able to support its operations in the near future. Here is what [[tagnumber 6]]NVLX [[tagnumber 7]]reported in their report for the second quarter of the year.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 23]] [[tagnumber 24]]cash: $2.89 million[[tagnumber 25]] [[tagnumber 24]]current assets: $3.06 million[[tagnumber 25]] [[tagnumber 24]]total assets: $8.19 million[[tagnumber 25]] [[tagnumber 24]]current and total liabilities: $371,386[[tagnumber 25]] [[tagnumber 24]]revenues: $0[[tagnumber 25]] [[tagnumber 24]]quarterly net loss: $1.58 million[[tagnumber 25]] [[tagnumber 36]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, despite the good news, [[tagnumber 6]]NVLX [[tagnumber 7]]couldn’t keep its upward direction and after it gapped up at $0.2517 at yesterday’s opening bell and reaching a high of $0.255 it began sliding, finally closing at $0.2419 or 2.06% down from the previous session. This time the volume was smaller and generated only $263 thousand in trade value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Being a pharmaceutical company in the development stage and considering the small percentile movements [[tagnumber 6]]NVLX [[tagnumber 7]]is, by all means, a long play. Just be sure to do your due diligence and weigh out the risks before putting your money on the line.[[tagnumber 2]]